테네시의 전이성 암 임상 시험
전이성 암 관련 연구 75개가 테네시 내 여러 지역에서 참여자를 모집하고 있습니다.
테네시의 도시
공식 연구 텍스트(영어)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Regional Cancer Center at Johnson City Medical Center, Johnson City
- Ballad Health Cancer Care - Kingsport, Kingsport
- 외 3개
피험자 모집 중2상
전 연령 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT06465069Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- West Cancer Center, Germantown
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology, Nashville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT07562152A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Tennessee Oncology, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT06270706A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
- Sarah Cannon Research Institute (SCRI), Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT06234605A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
피험자 모집 중1상
19세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT06586957Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT06625775A Study of ASP3082 in Adults With Advanced Solid Tumors
- Vanderbilt University Medical Center, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT05382559Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- University of Tennessee Medical Center, Knoxville
- Henry-Joyce Cancer Clinic, Nashville
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT06943755Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT05803382Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Henry-Joyce Cancer Clinic, Nashville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07222800A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07277413A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- St. Jude Children's Research Hospital, Memphis
피험자 모집 중1/2상
25세 이하 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT04094610Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Tennessee Oncology, PLLC - Chattanooga Downtown, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga - Medical Park II, Chattanooga
- Tennessee Oncology, PLLC - Franklin, Franklin
- 외 11개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07222566A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- Henry-Joyce Cancer Clinic, Nashville
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06989437A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
- SCRI Oncology Partners, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07612176A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Chattanooga
- Research Site, Nashville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06103864A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Sarah Cannon Research Institute, Nashville
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT05118789A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07218380A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Sarah Cannon Research Institute SCRI, Nashville
- Nashville General Hospital, Nashville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07174336Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06128551A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Vanderbilt University Medical Center, Nashville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07213804AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
- Tennessee Oncology PLLC, Nashville
피험자 모집 중1상
18세 ~ 99세 · 모든 성별 · 2026. 9. 21. 업데이트됨 · NCT07403721A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Tennessee Oncology, PLLC, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 21. 업데이트됨 · NCT07629960Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Sarah Cannon Research Institute, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT05267626Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Tennessee Oncology, PLLC- Chattanooga Downtown, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga Med Park II, Chattanooga
- Tennessee Oncology, PLLC - Chattanooga Memorial, Chattanooga
- 외 22개
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT07227415A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- The West Clinic, PLLC dba West Cancer Center ( Site 0005), Germantown
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT06863272Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT06566079CREO - Microwave Ablation Feasibility Study
- University of Tennessee Medical, Knoxville
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT07817147CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Clinical Study Site, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 10. 업데이트됨 · NCT07335497A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Center, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT06440005A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Nashville
피험자 모집 중3상
18세 ~ 130세 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT07647328NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
- Sarah Cannon Research Institute, Nashville
피험자 모집 중1상
19세 이상 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT07563829A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Tennessee Oncology Chattanooga, Chattanooga
- University of Tennessee Medical Center, Knoxville
- Baptist Memorial Hospital-Memphis, Memphis
- 외 2개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT06119581A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT06561685Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT06311214A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
- Sarah Cannon Research Institute - Tennessee Oncology, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT07213830A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- West Cancer Center, Germantown
피험자 모집 중1/2상
18세 이상 · 여성 · 2026. 9. 3. 업데이트됨 · NCT04802759A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- Sarah Cannon Research Institute-Tennessee Oncology, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT04913285ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.